Peptides for Weight Loss: What Is Approved, What Is Not

When people search for peptides for weight loss, they usually mean one of three very different things: FDA-approved prescription drugs such as Wegovy and Zepbound, experimental drugs still in clinical trials, or unapproved peptides sold online as “research chemicals.” Only the first group has been reviewed by the FDA for safety and effectiveness in weight management. This guide sorts the most-searched compounds into those groups and explains why “research use only” is a warning sign, not a loophole.

Peptide Labs does not sell semaglutide, tirzepatide, liraglutide or any prescription, investigational or unapproved peptide. This article is general information, not medical advice. Decisions about weight-management medicine belong with a licensed healthcare provider who knows your history.

What does "peptides for weight loss" mean?

A peptide is a short chain of amino acids. The FDA treats a chain of 40 amino acids or fewer as a peptide, and anything longer as a protein. Many hormones are peptides, including several gut hormones that help regulate appetite and blood sugar. (Our explainer on what peptides are covers the basics.)

The modern weight-management drugs grew out of research on those gut hormones, especially GLP-1 (glucagon-like peptide-1). Because the approved drugs are peptides, the word has become shorthand for a much wider online market, including compounds that have never been approved. Regulatory status is what separates them, so that is how this guide is organized.

FDA-approved peptides for weight loss

As of September 2026, these are the FDA-approved peptides for weight loss, meaning products whose labels include chronic weight management. Each requires a prescription, and each is approved for use alongside a reduced-calorie diet and increased physical activity.

• Semaglutide (Wegovy), made by Novo Nordisk, is a GLP-1 receptor agonist. The weekly injection was approved in 2021. On December 22, 2025 the FDA approved the Wegovy pill, a once-daily tablet and the first oral GLP-1 medicine approved for weight management. In the STEP 1 trial, adults on the injection lost about 15% of body weight on average over 68 weeks, versus about 2% on placebo. In the OASIS 4 trial of the pill, the average was 13.6% at 64 weeks, versus 2.2% on placebo. See our semaglutide profile.
• Tirzepatide (Zepbound), made by Eli Lilly, activates both the GIP and GLP-1 receptors. It was approved for chronic weight management in 2023 and for obstructive sleep apnea in adults with obesity in December 2024. In SURMOUNT-1, average weight loss was about 15% to 21% over 72 weeks depending on dose, versus about 3% on placebo. See our tirzepatide profile.
• Liraglutide (Saxenda) is an older, once-daily GLP-1 receptor agonist approved for weight management in 2014. In August 2025 the FDA approved the first generic version of Saxenda, making it the first generic GLP-1 medicine for weight loss. In the SCALE trial, average weight loss was 8.0% at 56 weeks versus 2.6% on placebo. See our liraglutide profile.
• Setmelanotide (Imcivree) is a peptide approved only for obesity caused by certain rare genetic conditions and, since March 2026, acquired hypothalamic obesity. It is not a general weight-loss drug.

Individual results vary widely. Digestive side effects such as nausea, vomiting, diarrhea and constipation are common, all three drugs carry a boxed warning about thyroid C-cell tumors, and studies show that much of the lost weight tends to return after treatment stops. For a side-by-side comparison of the two biggest names, read semaglutide vs tirzepatide.

What about Ozempic and Mounjaro?

Ozempic (semaglutide) and Mounjaro (tirzepatide) are the type 2 diabetes brands of the same molecules. Their labels do not include chronic weight management, although prescribers sometimes use them off-label. Our article on what “FDA-approved prescription drug” means explains why the approved use matters.

A newer option that is not a peptide

On April 1, 2026 the FDA approved orforglipron (Foundayo) from Eli Lilly for chronic weight management. It acts on the GLP-1 receptor, but it is a small-molecule pill rather than a peptide, so it does not belong on a list of peptides. In its main trial, ATTAIN-1, average weight loss at the highest dose was 12.4% at 72 weeks.

Investigational peptides still in clinical trials

Several newer peptides produced large average weight losses in trials, but none is FDA-approved. Outside an authorized clinical trial, they are not available as medicines in the United States.

• Retatrutide (Eli Lilly) acts on three receptors: GIP, GLP-1 and glucagon. Lilly reported phase 3 results in December 2025 (TRIUMPH-4) and July 2026 (TRIUMPH-2 and TRIUMPH-3), with average weight loss of up to 28.7% at 68 weeks in adults with knee osteoarthritis. The company has said it plans to file with the FDA in the first quarter of 2027.
• CagriSema (Novo Nordisk) combines semaglutide with cagrilintide, a long-acting amylin analog. In the REDEFINE 1 trial, average weight loss was 20.4% at 68 weeks versus 3.0% on placebo. Novo Nordisk submitted it to the FDA in December 2025, and the application is under review. Cagrilintide on its own is also investigational.
• Survodutide (Boehringer Ingelheim) acts on the glucagon and GLP-1 receptors. In the phase 3 SYNCHRONIZE-1 trial, reported in June 2026, adults without diabetes lost up to 16.6% of body weight on average at 76 weeks, versus 3.2% on placebo.
• Mazdutide is a glucagon and GLP-1 dual agonist that China’s regulator approved for weight management in June 2025. That approval does not apply in the United States.

Peptides marketed online without FDA approval

A separate group of peptides is promoted on social media and “research chemical” websites for fat loss, often with before-and-after claims. None of them is FDA-approved for weight loss, and most have little or no controlled human data.

• AOD-9604 is a fragment of human growth hormone that was studied for obesity in the 2000s. Development stopped, and it is not approved for any use.
• MOTS-c is a mitochondrial-derived peptide studied mainly in cells and animals. It is not FDA-approved.
• Adipotide was designed to target the blood supply of fat tissue. Research has been early stage and mostly in animals.
• CJC-1295, ipamorelin and the CJC-1295/ipamorelin blend are growth hormone secretagogues. None is an approved medicine.
• Tesamorelin is FDA-approved, but only as Egrifta, to reduce excess abdominal fat in adults with HIV who have lipodystrophy. It is not approved for general weight loss.

Weight-loss peptides compared: U.S. status in 2026

Every compound here has a profile in our Peptide Guide, which lists the U.S. regulatory status of 49 peptides.

Why "research use only" peptides are a risk

Many websites sell semaglutide, tirzepatide, retatrutide and other peptides as powders or vials labeled “research use only” or “not for human consumption.” The FDA does not accept that label at face value. In warning letters dated March 31, 2026 and August 24, 2026, the agency told online sellers of these products that evidence on their websites established the products were intended as drugs for human use, which makes them unapproved new drugs.

For the person using them, the problems are serious:

• No regulator has checked what is in the vial, how much of it, or whether it is sterile.
• The FDA has flagged risks of immune reactions and peptide-related impurities for several peptides promoted online.
• Retatrutide and the other investigational drugs have no approved label, so there is no established safety information outside the trials.
• No pharmacist, prescriber or recall system stands behind the product.

Athletes face an extra issue: the World Anti-Doping Agency prohibits many of these peptides, including AOD-9604, CJC-1295 and ipamorelin. Our guide to whether peptides are legal explains how U.S. law treats each category.

Is there an honest "Ozempic alternative"?

People searching for an Ozempic alternative usually want something cheaper, easier to get, or without injections. The honest answer is that the alternatives with FDA-reviewed evidence for weight management are other prescription medicines: Wegovy (injection or pill), Zepbound, liraglutide (including generics), orforglipron, and older non-peptide drugs a prescriber can discuss. Which one fits depends on health history, side effects, coverage and cost.

Compounded copies, “research” peptides and supplements are not equivalent substitutes. Compounded semaglutide and tirzepatide face tight limits now that the shortages are over, which we cover in our guide to compounded semaglutide and tirzepatide.

How OTC "GLP-1" supplements differ

Many over-the-counter products carry “GLP-1” on the label. They are dietary supplements, usually based on fiber, berberine, probiotics or plant extracts. They do not contain semaglutide, tirzepatide or any other GLP-1 drug, and they are not FDA-approved to treat obesity. Our guide to what “GLP-1 support” labels mean goes into detail, and our buyer’s guide explains how to read a supplement label.

Frequently Asked Questions

Last reviewed September 2026. Drug approvals, trial results and FDA policies change; check the current prescribing information or ask a pharmacist for the latest details. These statements are general information and are not a substitute for advice from a licensed healthcare provider.